NIH funding for vaccine readiness before the COVID-19 pandemic

• Published in: Vaccine Vol. 39; no. 17; pp. 2458 - 2466
• Main Authors: Kiszewski, Anthony E., Cleary, Ekaterina Galkina, Jackson, Matthew J., Ledley, Fred D.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 22.04.2021; Elsevier Limited; The Authors. Published by Elsevier Ltd
• Subjects: Allergy and Immunology; Bibliometrics; Clinical trials; Coronaviruses; COVID-19; COVID-19 infection; COVID-19 Vaccines; dengue; Dengue fever; Deoxyribonucleic acid; Disease transmission; DNA; Funding; Gene therapy; Grants; Health risks; Humans; Innovations; mRNA vaccines; New technology; NIH Funding; pandemic; Pandemics; Public health; Public sector; Respiratory diseases; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccine; Vaccines; Vector-borne diseases; Vectors (Biology); Viral diseases; Viruses; Zika Virus; Zika Virus Infection - epidemiology; Zika Virus Infection - prevention & control; COVID-19; SARS-CoV-2; CEPI; NIH Funding; RePORT; TLR9; MeSH; Vaccine; TIME; PMID; WHO; World Health Organization; Technology Innovation Maturation Evaluation (model); (NIH) Research Portfolio Online Reporting Tools; PubMed Identifiers; toll-like receptor 9; Coalition for Epidemic Preparedness Innovations; Medical Subject Headings
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2021.03.022

•Rapid development of COVID-19 vaccines was enabled by existing vaccine technologies.•NIH funded $17.2 billion in published research on vaccine technologies prior to 2020.•NIH funding for published research on vaccines for pandemic threats has been inconsistent.•Sustained funding for enabling technology critical for rapid response to emerging threats. Rapid development of vaccines for COVID-19 has relied on the application of existing vaccine technologies. This work examines the maturity of ten technologies employed in candidate vaccines (as of July 2020) and NIH funding for published research on these technologies from 2000–2019. These technologies vary from established platforms, which have been used successfully in approved products, to emerging technologies with no prior clinical validation. A robust body of published research on vaccine technologies was supported by 16,358 fiscal years of NIH funding totaling $17.2 billion from 2000–2019. During this period, NIH funding for published vaccine research against specific pandemic threats such as coronavirus, Zika, Ebola, and dengue was not sustained. NIH funding contributed substantially to the advance of technologies available for rapid development of COVID-19 vaccines, suggesting the importance of sustained public sector funding for foundational technologies in the rapid response to emerging public health threats.